A higher percentage of cancer cells bearing the mutated EGFR gene within the tumor was highly correlated with better responsiveness, longer progression-free survival and overall survival in mutEGFR NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.